t
MedPal AI plc announced on April 2, 2026, a replacement statement correcting that RPGC Crouch Chapman LLP were reappointed as auditors, not Grant Thornton Limited, as previously stated. At the Annual General Meeting held on the same date, all nine resolutions were passed, including the re-election of four directors and the reappointment of auditors, with votes in favour ranging from 99.80% to 99.98% across resolutions and approximately 45.6% of the issued share capital being voted.
| Date | 2 Apr 2026 |
| Time | 10:44:55 |
| Category | AGMs and other meetings |
| ID | 2773Z |
2 April 2026
MedPal AI plc
("MedPal AI" or the "Company")
Result of AGM - Replacement
This announcement replaces the announcement of 30 March 2026. The Company's auditors being reappointed per resolution 6 are RPGC Crouch Chapman LLP, not Grant Thornton Limited as previously stated. All other details remain the same.
MedPal AI plc (AIM:MPAL, FRA Z1N), the digital health and AI company, announces that, at the annual general meeting of the Company held today, all of the resolutions were passed. The results of the poll vote are set out below.
|
Summary of Resolutions |
For |
Percentage of votes in Favour |
Against |
Percentage of votes Against |
Withheld |
Total of issued share capital voted |
Percentage of issued share capital voted |
|
1 Receive the consolidated annual report and accounts for the year ended 31 August 2025 |
224,919,529 |
99.98% |
38,956 |
0.02% |
116,470 |
224,958,485 |
45.68% |
|
2 Reappoint Jason Drummond as a director of the Company |
224,809,794 |
99.95% |
122,314 |
0.05% |
142,847 |
224,932,108 |
45.68% |
|
3 Reappoint Kevin O'Neill as a director of the Company |
224,811,214 |
99.95% |
120,894 |
0.05% |
142,847 |
224,932,108 |
45.68% |
|
4 Reappoint Justin Drummond as a director of the Company |
224,869,171 |
99.97% |
65,279 |
0.03% |
140,505 |
224,934,450 |
45.68% |
|
5 Reappoint Adam Monaco as a director of the Company |
224,810,542 |
99.95% |
121,391 |
0.05% |
143,022 |
224,931,933 |
45.68% |
|
6 Reappoint RPGC Crouch Chapman LLP as auditors |
224,805,257 |
99.96% |
100,743 |
0.04% |
168,955 |
224,906,000 |
45.67% |
|
7 To authorise the Directors to determine the fees payable to the auditors |
224,632,019 |
99.92% |
190,457 |
0.08% |
252,479 |
224,822,476 |
45.65% |
|
8 To authorise the Directors to allot ordinary shares and relevant securities pursuant to Section 551 of the Companies Act 2006.
|
224,514,082 |
99.80% |
445,098 |
0.20% |
115,775 |
224,959,180 |
45.68% |
|
9 To disapply pre-emption rights in certain circumstances (general authority). |
224,643,956 |
99.88% |
271,975 |
0.12% |
159,024 |
224,915,931 |
45.67% |
Notes:
A vote "withheld" is not a vote in law and has not been counted as a vote "for" or "against" a resolution.
Resolutions 1 to 8 were passed as Ordinary Resolutions. Resolution 9 was passed as a Special Resolution
The number of ordinary shares in issue at the date of this announcement is 492,441,036, of which no ordinary shares are held in treasury.
Enquiries:
|
MedPal AI plc Jason Drummond, Chief Executive Officer
|
Via Square1 Consulting |
|
Cairn Financial Advisers LLP Louise O'Driscoll/Jo Turner
|
+44 (0) 20 7213 0880 |
|
Clear Capital Markets Limited Bob Roberts
|
+44 (0) 20 3869 6080 |
|
Square1 Consulting David Bick |
+44 (0) 20 7929 5599 +44 (0) 7831 381201 |
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.